Bill Anderson/LinkedIn
Nov 26, 2025, 11:37
Bill Anderson on Secondary Stroke Prevention: This Week, We’ve Reached a Significant Milestone
Bill Anderson, CEO at Bayer, shared on LinkedIn:
”Those numbers tell the story: stroke is devastating.
For patients. For families.
And after surviving, the risk of another stroke is even higher.
This week, we’ve reached a significant milestone with positive topline results from our international Phase III study in secondary stroke prevention.
Our teams worked hard to get here.
Thank you, Team Bayer, for pushing to help people who’ve already been through so much.
We’re making progress—and there’s more to do.”

Stay updated with Hemostasis Today.
-
Aug 11, 2026, 11:47Rucha Patil: Strengthening Evidence-Based Haemophilia Care Across India
-
Aug 11, 2026, 11:38Maria Hadjidemetriou: The Patient Perspective in Thalassemia Care
-
Aug 11, 2026, 11:04Wolfgang Miesbach: The Critical Need for Tailored Dosing in VWD
-
Aug 11, 2026, 08:20Hasan Abbas Zaheer: Strengthening Universal Access to Safe Blood in Pakistan
-
Aug 11, 2026, 08:07Nicola Pozzi: Advancing Hemostasis Through Scientific Collaboration at Hemostasis GRC
-
Aug 11, 2026, 07:50When Access to Care Changes Everything – WFH
-
Aug 11, 2026, 07:41Kevin Land: How Cellular Therapy Is Changing Transfusion Medicine
-
Aug 11, 2026, 07:35Kuldeep Singh Bhadauria: Building the Future of Hemophilia Care in India
-
Aug 11, 2026, 07:28Archil Jaliashvili: When Every Minute Matters Time Becomes a Therapy